Medacta Group SA · SIX:MOVE
Medacta Group SA — FY2021 Earnings Presentation
20 slides from Medacta Group SA's earnings presentation, Mar 11, 2022
Slide 1: FY 2021 Financial Results
FY 2021 FINANCIAL RESULTS 11 March 2022
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the presentation does not purport to be comprehensive. Please refer to the Medacta 2021 Annual Report available on our website at
Slide 3: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer FY 2021 Financial Results
Slide 4: 2021 Key Financial Figures
2021 KEY FINANCIAL FIGURES* * Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency", "EBITDA", "Adjusted EBITDA" or “CORE EBITDA”, "Free Cash Flow", “Adjusted Free Cash
Slide 5: Medacta's Achievements
FY 2021 Medacta’s Achievements In 2021 Medacta’s revenue increased by 21.4% from 2020 at constant currency, to EUR 363.1 million Revenue growth from 2019 was equal to 18.9% at constant currency Adjusted EBITDA grew to EUR 107.1 million, corresponding to 29.5% margin Profit for the year incre
Slide 6: Deployment of the NextAR AR Surgical Platform
DEPLOYMENT OF THE NEXTAR™ AR SURGICAL PLATFORM NextAR, our Augmented Reality Surgical Platform, empowers the surgeon’s vision with real-time surgical guidance superimposed onto the operative field to make data-driven decision-making NextAR is the first platform to offer Augmented Reality solutio
Slide 7: Innovation and Product Development
INNOVATION AND PRODUCT DEVELOPMENT Hip – Further enhancement of the AMIS® technique with the Bikini offering – Expansion of our revision platform – As innovative technologies, personalized solutions with 3D preoperative planning and intraoperative verification (MyHip® Planner and MyHip® Verifier),
Slide 8: Marketing and Medical Education Programs
MARKETING AND MEDICAL EDUCATION PROGRAMS Medical Education back to normal level with significant increase compared to 2019 Decentralized marketing and educational activities proved to be very effective at engaging surgeons and supporting customer acquisition Further strengthening of the M.O.R.
Slide 9: Corrado Farsetta, Chief Financial Officer
CORRADO FARSETTA Chief Financial Officer FY 2021 Financial Results
Slide 10: Revenue Bridge vs 2020 by Product Line
FY 2021 REVENUE BRIDGE VS 2020 BY PRODUCT LINE1 Constant currency (€m) 17.8% 24.8% 35.4% 20.4% 21.4% 20.0% (€m) 19.0; 33.8; 5% 9% 179.3; 131.1; 50% 36% 2 Hip Knee Extremities Spine Hip: growth driven by the AMIS® strategy supported by the roll-out of new products Knee: good momentum generated by
Slide 11: Revenue Bridge vs 2020 by Geographic Area
FY 2021 REVENUE BRIDGE VS 2020 BY GEOGRAPHIC AREA1 Constant currency (€m) 21.2% 21.9% 17.5% 50.3% 21.4% 20.0% (€m) 12.6; 4% 84.9; 23% 156.4; 43% 109.2; 30% Europe NA APAC ROW Europe: solid growth across all countries despite COVID-19 restrictions in Q1 and Q4 North America: customer acquisition,
Slide 12: Revenue Bridge vs 2019
FY 2021 REVENUE BRIDGE VS 20191 Growth by Product Line 10.7% 19.7% 98.5% 38.2% 18.9% 16.9% 2 YEARS GROWTH FROM 2019 In 2021 the growth rate was equal to 21.4% from a (€m) 2020 heavily affected by COVID-19. To better assess our performance, we analyzed our growth from a pre-COVID period, which was eq
Slide 13: P&L: Remarkable Profitability
FY 2021 P&L: REMARKABLE PROFITABILITY1 2 3 Notes: 1. For a reconciliation of Alternative Performance Measures please refer to section headed “Alternative Performance Measures” of the Annual Report. The 2021 Annual Report is available at https://www.medacta.com/EN/financial-reports. 2 Adjusted EBITDA
Slide 14: Investments for Future Growth
FY 2021 INVESTMENTS FOR FUTURE GROWTH FY 2021 Investments €52.0m % of Revenues 14.3% (€m) Other Intangibles;3 R&D 1.8 Investments; 6.3 Other Tangibles;2 8.9 Instruments;1 35.0 Notes: 1. Instruments are netted by proceeds from sale of tangible assets 2. Other Tangibles include plant & machinery, fixt
Slide 15: Positive Free Cash Flow After Significant Investments
FY 2021 POSITIVE FREE CASH FLOW1 AFTER SIGNIFICANT INVESTMENTS TO FUND THE FUTURE GROWTH Notes: 1. For a reconciliation of Alternative Performance Measures please refer to section headed “Alternative Performance Measures” of the Annual Report. The 2021 Annual Report is available at https://www.medac
Slide 16: Net Financial Debt: We Continue Decreasing Our Leverage
NET FINANCIAL DEBT: WE CONTINUE DECREASING OUR LEVERAGE1,2 Leverage 0.95x 0.87x (€M) (93.6) (83.3) Net Debt at 31 December 2020 Net Debt at 31 December 2021 Notes: 1. For a reconciliation of Alternative Performance Measures please refer to section headed “Alternative Performance Measures” of the Ann
Slide 17: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer FY 2021 Financial Results
Slide 18: 2022 Outlook
2022 Outlook In 2022 we will continue to prioritize our future growth through a further expansion of our international salesforce, with a focus on the US market. In addition, we remain committed on product innovation with several full market releases expected during the year, starting from the sho
Slide 19: Q&A
Q&A FY 2021 Financial Results
Slide 20: Adedacta International
Adedacta Adedacta International